ESMO 2020: Addition of Atezolizumab to Paclitaxel Treatment for Triple-Negative Breast Cancer Shows No Significant Benefit
Author states that further exploration is required to reconcile the disparity in results with previous studies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.